
Elena Verrecchia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8201212/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rapid resolution of severe pericardial effusion using anakinra in a patient with COVID-19 vaccine-related acute pericarditis relapse: a case report. European Heart Journal - Case Reports, 2022, 6, ytac123.	0.6	5
2	Caregivers' and Physicians' Perspectives on Alpha-Mannosidosis: A Report from Italy. Advances in Therapy, 2021, 38, 1-10.	2.9	4
3	Right ventricular strain in Anderson-Fabry disease. International Journal of Cardiology, 2021, 330, 84-90.	1.7	10
4	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. Rheumatology, 2021, 60, 5705-5712.	1.9	4
5	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. Frontiers in Medicine, 2021, 8, 668173.	2.6	6
6	Children and Adults with PFAPA Syndrome: Similarities and Divergences in a Real-Life Clinical Setting. Advances in Therapy, 2021, 38, 1078-1093.	2.9	15
7	The Use of Chitotriosidase as a Marker of Active Sarcoidosis and in the Diagnosis of Fever of Unknown Origin (FUO). Journal of Clinical Medicine, 2021, 10, 5283.	2.4	6
8	Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e20200059.	1.3	2
9	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- <i>α</i> Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	3.0	24
10	Prognostic significance of right ventricular hypertrophy and systolic function in Anderson–Fabry disease. ESC Heart Failure, 2020, 7, 1605-1614.	3.1	14
11	Mesothelioma in Familial Mediterranean Fever With Colchicine Intolerance: A Case Report and Literature Review. Frontiers in Immunology, 2020, 11, 889.	4.8	8
12	Macular Impairment in Fabry Disease: A Morpho-functional Assessment by Swept-Source OCT Angiography and Focal Electroretinography. , 2019, 60, 2667.		23
13	Rare missense variants in the ALPK1 gene may predispose to periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. European Journal of Human Genetics, 2019, 27, 1361-1368.	2.8	21
14	New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases. CKJ: Clinical Kidney Journal, 2019, 12, 65-70.	2.9	10
15	Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two) Tj ETQq1 1 2018, 481, 25-33.	0.784314 1.1	f rgBT /Over o 13
16	Clinical hints to diagnosis of attenuated forms of Mucopolysaccharidoses. Italian Journal of Pediatrics, 2018, 44, 132.	2.6	25
17	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	2.2	64
18	Resolution of femoral metaphyseal dysplasia in CINCA syndrome after long-term treatment with interleukin-1 blockade. Clinical Rheumatology, 2018, 37, 2007-2009.	2.2	7

Elena Verrecchia

#	Article	IF	CITATIONS
19	Right Ventricular Hypertrophy, Systolic Function, and Disease Severity in Anderson-Fabry Disease: An Echocardiographic Study. Journal of the American Society of Echocardiography, 2017, 30, 282-291.	2.8	31
20	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. Internal and Emergency Medicine, 2017, 12, 1059-1067.	2.0	7
21	Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. Frontiers in Immunology, 2017, 8, 1018.	4.8	37
22	Small Intestinal Bacterial Overgrowth Affects the Responsiveness to Colchicine in Familial Mediterranean Fever. Mediators of Inflammation, 2017, 2017, 1-6.	3.0	14
23	Anderson-Fabry's Disease: A Rare but Treatable Case of Fever of Unknown Origin. European Journal of Case Reports in Internal Medicine, 2017, 2, 000645.	0.4	0
24	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	3.5	72
25	Switch from anakinra to canakinumab in a severe case of CINCA syndrome. International Journal of Rheumatic Diseases, 2016, 19, 1354-1356.	1.9	3
26	The impact of fever/hyperthermia in the diagnosis of Fabry: A retrospective analysis. European Journal of Internal Medicine, 2016, 32, 26-30.	2.2	9
27	Colchicine trial in PFAPA Syndrome and MEFV-negative patients. Pediatric Rheumatology, 2015, 13, .	2.1	2
28	PFAPA syndrome as an hereditary autoinflamatory disorder. Pediatric Rheumatology, 2015, 13, .	2.1	0
29	Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmunity Reviews, 2014, 13, 1220-1229.	5.8	86
30	Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus, 2012, 21, 153-157.	1.6	61
31	Effectiveness of Colchicine Therapy in 4 Cases of Retroperitoneal Fibrosis Associated with Autoinflammatory Diseases. Journal of Rheumatology, 2010, 37, 1971-1972.	2.0	7
32	Familial Mediterranean Fever: A review for clinical management. Joint Bone Spine, 2009, 76, 227-233.	1.6	99
33	La maladie périodique. Revue Du Rhumatisme (Edition Francaise), 2009, 76, 382-389.	0.0	1
34	Efficacy of etanercept in the treatment of a patient with Behçet's disease. Clinical Rheumatology, 2008, 27, 933-936.	2.2	27
35	Wegener's granulomatosis: an update on diagnosis and therapy. Expert Review of Clinical Immunology, 2008, 4, 481-495.	3.0	3
36	Folic acid supplementation during methotrexate treatment: nonsense?. British Journal of Rheumatology, 2005, 44, 563-564.	2.3	2